Lymphoma of the Eye - rates increasing

Reuters Health reports that from 1975 to 2001, a rapid and steady rise in the rate of ocular non-Hodgkin lymphoma (NHL) occurred, and there is still no evidence the disease has peaked, according to a new report.



The findings, which appear in the Journal of the National Cancer Institute for July 5 (J Natl Cancer Inst 2006;98:936-939), are based on analysis of data from the Surveillance, Epidemiology, and End Results (SEER) Program.



Asians/Pacific Islanders had the highest rates of ocular NHL, around 0.33 cases per 100,000 person-years, lead author Dr. Roxana Moslehi, from the National Cancer Institute in Rockville, Maryland, and colleagues state. Whites had the next highest rate, roughly 0.27 cases per 100,000 person-years. Blacks and American Indian/Alaska native had the lowest rates.



Advancing age was identified as a risk factor for ocular NHL. In contrast to other NHLs, which typically showed an increased risk for men, gender seemed to have no bearing on the risk of ocular NHL.



During the 27-year study period, the incidence of ocular NHL in men and women climbed by 6.2% and 6.5% each year, respectively. As noted, there were no signs that disease rates were now leveling off.



As to why the rapid increase in cases, the authors suggest that it may relate to infection with Chlamydia psittaci, a microbe that has been tied to ocular NHL in the past. Further studies are needed to explore this possibility, they add.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap